Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics Ltd. (AU:ZLD)
:ZLD
ZLD Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.28 - AU$1.09
Previous CloseN/A
Volume190.00
Average Volume (3M)2.06K
Market Cap
AU$5.56M
Enterprise ValueAU$6.77M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.22
Shares Outstanding11,347,155
10 Day Avg. Volume883
30 Day Avg. Volume2,057
Standard Deviation0.40
R-Squared0.03
Alpha-0.00771
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)454.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Zelira Therapeutics News
PremiumCompany Announcements
Zelira Therapeutics Advances HOPE® Program with Secured FDA Trial Funding
PremiumCompany Announcements
Zelira Therapeutics Secures Fourth Funding Tranche to Advance FDA Trials
PremiumCompany Announcements
Zelira Therapeutics Announces Change in Director’s Interest
PremiumCompany Announcements
Zelira Therapeutics Issues Convertible Notes
PremiumCompany Announcements
Zelira Therapeutics Issues 3.5 Million Convertible Notes
PremiumCompany Announcements
Zelira Therapeutics Unveils Growth Plans at Investment Conference
PremiumCompany Announcements
Zelira Therapeutics Secures Shareholder Support at AGM---
ZLD FAQ
What was Zelira Therapeutics Ltd.’s price range in the past 12 months?
Zelira Therapeutics Ltd. lowest share price was AU$0.28 and its highest was AU$1.09 in the past 12 months.
What is Zelira Therapeutics Ltd.’s market cap?
Zelira Therapeutics Ltd.’s market cap is AU$5.56M.
When is Zelira Therapeutics Ltd.’s upcoming earnings report date?
Zelira Therapeutics Ltd.’s upcoming earnings report date is Aug 27, 2025 which is in 187 days.
How were Zelira Therapeutics Ltd.’s earnings last quarter?
Zelira Therapeutics Ltd. released its earnings results on Aug 28, 2024. The company reported -AU$0.214 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.214.
Is Zelira Therapeutics Ltd. overvalued?
According to Wall Street analysts Zelira Therapeutics Ltd.’s price is currently Overvalued.
Does Zelira Therapeutics Ltd. pay dividends?
Zelira Therapeutics Ltd. does not currently pay dividends.
What is Zelira Therapeutics Ltd.’s EPS estimate?
Zelira Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics Ltd. have?
Zelira Therapeutics Ltd. has 11,347,155 shares outstanding.
What happened to Zelira Therapeutics Ltd.’s price movement after its last earnings report?
Zelira Therapeutics Ltd. reported an EPS of -AU$0.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2%.
Which hedge fund is a major shareholder of Zelira Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ZLD
---
Zelira Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:ZLD Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.64%
12-Months-Change
Fundamentals
Return on Equity
-263.02%
Trailing 12-Months
Asset Growth
-84.65%
Trailing 12-Months
Company Description
Zelira Therapeutics Ltd.
Zelira Therapeutics Ltd, formerly Zelda Therapeutics Ltd is an Australia-based biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in a breast, brain, and pancreatic cancer.
---
Technical Analysis
---